William Mietlowski

2.4k total citations · 1 hit paper
32 papers, 1.8k citations indexed

About

William Mietlowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, William Mietlowski has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in William Mietlowski's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (4 papers). William Mietlowski is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (4 papers). William Mietlowski collaborates with scholars based in United States, Switzerland and Germany. William Mietlowski's co-authors include Margaret Dugan, Barbara Waßmann, Jörge E. Cortes, P. Rae, Maher Albitar, Oliver G. Ottmann, Leila Alland, Francis J. Giles, Hagop M. Kantarjian and Andreas Hochhaus and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

William Mietlowski

31 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine profile →

Peers

William Mietlowski

HEMAT

GENET

ONCOL

RHEUM

Aaron Weitzman United States

Chao Zhu China

Sara Redaelli Italy

Taxiarchis Kourelis United States

David M. Ross Australia

Heather Landau United States

Steven Knapper United Kingdom

Anne Blackwood‐Chirchir United States

W. Paul Bowman United States

Scott Cruickshank United States

Aaron Weitzman United States

William Mietlowski

687 ×0.8

HEMAT

570 ×0.8

GENET

329 ×0.7

ONCOL

421 ×0.9

RHEUM

181 ×0.5

Citations per year, relative to William Mietlowski William Mietlowski (= 1×) peers Aaron Weitzman

Countries citing papers authored by William Mietlowski

Since Specialization

Citations

This map shows the geographic impact of William Mietlowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Mietlowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Mietlowski more than expected).

Fields of papers citing papers by William Mietlowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Mietlowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Mietlowski. The network helps show where William Mietlowski may publish in the future.

Co-authorship network of co-authors of William Mietlowski

This figure shows the co-authorship network connecting the top 25 collaborators of William Mietlowski. A scholar is included among the top collaborators of William Mietlowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Mietlowski. William Mietlowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mietlowski, William, Andrew M. Stein, Weichao Bao, Roger J. Waltzman, & Patricia A. Wood. (2013). Prognostic value of waterfall plots with the addition of nontarget lesion data.. Journal of Clinical Oncology. 31(15_suppl). 11082–11082. 1 indexed citations

Baselga, José, Alain C. Mita, Patrick Schöffski, et al.. (2012). Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research. 18(22). 6364–6372. 14 indexed citations

Reardon, David A., Charles A. Conrad, Timothy F. Cloughesy, et al.. (2012). Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69(6). 1507–1518. 50 indexed citations

Stein, Andrew M., Joaquim Bellmunt, Bernard Escudier, et al.. (2012). Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. European Urology. 64(6). 994–1002. 30 indexed citations

Reardon, David A., Timothy F. Cloughesy, Jeremy N. Rich, et al.. (2011). Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemotherapy and Pharmacology. 69(1). 281–287. 11 indexed citations

Kovalchik, Stephanie & William Mietlowski. (2010). Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint. Contemporary Clinical Trials. 32(1). 99–107. 14 indexed citations

Davis, Darren W., Jing Huang, William P. Steward, et al.. (2007). Pharmacodynamic analysis of receptor tyrosine kinase (RTK) activity reveals differential target inhibition in skin and tumor in a phase I study of advanced colorectal cancer patients treated with AEE788. Journal of Clinical Oncology. 25(18_suppl). 3601–3601. 2 indexed citations

Kantarjian, Hagop M., Francis J. Giles, Lydia Wunderle, et al.. (2006). Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL. New England Journal of Medicine. 354(24). 2542–2551. 970 indexed citations breakdown →

Helle, Svein Inge, William Mietlowski, Jean Paul Guastalla, et al.. (2005). Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. European Journal of Cancer. 41(5). 694–701. 7 indexed citations

10.

Reardon, Dean B., Timothy F. Cloughesy, C. Conrad, et al.. (2005). A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Journal of Clinical Oncology. 23(16_suppl). 3063–3063. 22 indexed citations

11.

Giles, Francis J., Hagop M. Kantarjian, Barbara Waßmann, et al.. (2004). A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).. Blood. 104(11). 22–22. 26 indexed citations

12.

Mudholkar, Govind S., Gregory E. Wilding, & William Mietlowski. (2003). Robustness Properties of the Pitman–Morgan Test. Communication in Statistics- Theory and Methods. 32(9). 1801–1816. 11 indexed citations

13.

Li, David K.B., Jerry S. Wolinsky, R. A. Koopmans, et al.. (1997). Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis. Journal of Neuroimaging. 7(1). 1–7. 28 indexed citations

14.

Shupack, Jerome L., Elizabeth Abel, Eugene A. Bauer, et al.. (1997). Cyclosporine as maintenance therapy in patients with severe psoriasis. Journal of the American Academy of Dermatology. 36(3). 423–432. 78 indexed citations

15.

Appel, Stanley H., Scott Stewart, Vicki Appel, et al.. (1988). A Double-blind Study of the Effectiveness of Cyclosporine in Amyotrophic Lateral Sclerosis. Archives of Neurology. 45(4). 381–386. 76 indexed citations

16.

Abramson, Neil, et al.. (1982). Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.. PubMed. 66(6). 1273–7. 20 indexed citations

17.

Seydel, H. Gunter, Richard H. Creech, William Mietlowski, & Carlos A. Perez. (1979). Preliminary report of a cooperative randomized study for the treatment of localized small cell lung carcinomat. International Journal of Radiation Oncology*Biology*Physics. 5(9). 1445–1447. 15 indexed citations

18.

Hyde, Leroy, Julius Wolf, Roswell W. Phillips, & William Mietlowski. (1978). Combined Chemotherapy for Squamous Cell Carcinoma of the Lung. CHEST Journal. 73(5). 603–607. 14 indexed citations

19.

Moss, Alastair J., et al.. (1975). Prognostic grading and significance of ventricular premature beats after recovery from myocardial infarction.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 52(6 Suppl). III204–10. 41 indexed citations

20.

Morgan, John P., William M. Wardell, Louis Lasagna, et al.. (1973). Mebutamate as a hypnotic: Clinical trial and statistical considerations. Clinical Pharmacology & Therapeutics. 14(6). 1001–1012. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact